Skip to main content

Talk Bio

Search This Blog

How one biotech is using 'digital twins' to study a muscle disease therapy

on June 29, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Epicrispr Biotechnologies is using "digital twins" to study a muscle disease therapy targeting facioscapulohumeral muscular dystrophy (FSHD).

Epicrispr has developed an epigenetic editing therapy named EPI-321 aimed at increasing expression of the DUX4 gene, which is associated with FSHD, and using AI to generate early cut data showing lean muscle gains.

The use of digital twins in this context allows the company to simulate and predict how the therapy will affect muscle tissue and functional outcomes, supplementing real-world clinical data and enabling more efficient drug development.

Sources:

Advancing rare disease therapeutics through digital twins - PMC - NIH

The Digital Twin: A Potential Solution for the Personalized Diagnosis ...

MyoStride: Portable HD-EMG-driven digital human twins in the clinical practice | Projects | Department of Biomechanical Engineering

Framework of a multiscale data-driven digital twin of the muscle ...

Digital Twins Power Early Diagnosis & Targeted Therapy

Digital Twin of the Musculoskeletal System | MaD Lab

BREAKOUT 1 - Digitalized Medicine: Digital twins of human neuromusculoskeletal system

PHD2024-15 | Digital twins of organoids by multi-scale modeling

News - Epicrispr Biotechnologies

[PDF] Based Digital Twins Approach Supplements Clinical Trial ... - ASCPT

ORBilu: Digital twin systems for musculoskeletal applications

Immune digital twins for complex human pathologies: applications, limitations, and challenges

Digital Twins of Biological Systems Inform Drug Development

Quantitative Systems Pharmacology-Based Digital Twins Approach ...

A myoelectric digital twin for fast and realistic modelling in deep learning - PubMed

digital twins EPI-321 Epicrispr Biotechnologies epigenetic editing gains lean muscle muscle disease therapy Muscular Dystrophy, Facioscapulohumeral

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Powered by Blogger

X-Data LLC